MX2013000319A - Tratamiento de transtornos cognitivos. - Google Patents
Tratamiento de transtornos cognitivos.Info
- Publication number
- MX2013000319A MX2013000319A MX2013000319A MX2013000319A MX2013000319A MX 2013000319 A MX2013000319 A MX 2013000319A MX 2013000319 A MX2013000319 A MX 2013000319A MX 2013000319 A MX2013000319 A MX 2013000319A MX 2013000319 A MX2013000319 A MX 2013000319A
- Authority
- MX
- Mexico
- Prior art keywords
- treatment
- cognitive disorders
- disorders
- vitamin
- subject
- Prior art date
Links
- 208000010877 cognitive disease Diseases 0.000 title abstract 3
- 238000011282 treatment Methods 0.000 title abstract 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 abstract 2
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 abstract 2
- FFFHZYDWPBMWHY-VKHMYHEASA-N L-homocysteine Chemical compound OC(=O)[C@@H](N)CCS FFFHZYDWPBMWHY-VKHMYHEASA-N 0.000 abstract 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 abstract 1
- 229930003779 Vitamin B12 Natural products 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 235000019152 folic acid Nutrition 0.000 abstract 1
- 239000011724 folic acid Substances 0.000 abstract 1
- 229960000304 folic acid Drugs 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 abstract 1
- 235000019156 vitamin B Nutrition 0.000 abstract 1
- 239000011720 vitamin B Substances 0.000 abstract 1
- 235000019163 vitamin B12 Nutrition 0.000 abstract 1
- 239000011715 vitamin B12 Substances 0.000 abstract 1
- 235000019158 vitamin B6 Nutrition 0.000 abstract 1
- 239000011726 vitamin B6 Substances 0.000 abstract 1
- 229940011671 vitamin b6 Drugs 0.000 abstract 1
- 150000003722 vitamin derivatives Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7135—Compounds containing heavy metals
- A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4415—Pyridoxine, i.e. Vitamin B6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La invención se refiere a tratamientos de trastornos cognitivos, por ejemplo el trastorno cognitivo leve, que comprende el uso de agentes que son capaces de disminuir los niveles de homocisteína en un sujeto, preferiblemente en un sujeto humano; algunos aspectos de la invención se refieren a un método para tratar tales trastornos, que comprende administrar una o más vitaminas B, por ejemplo ácido fólico, vitamina B6 y/o vitamina B12 o derivados de las mismas.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US36075910P | 2010-07-01 | 2010-07-01 | |
| PCT/GB2010/051557 WO2012001336A1 (en) | 2010-07-01 | 2010-09-17 | Treatment of cognitive disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2013000319A true MX2013000319A (es) | 2013-05-01 |
Family
ID=43127076
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2013000319A MX2013000319A (es) | 2010-07-01 | 2010-09-17 | Tratamiento de transtornos cognitivos. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US9364497B2 (es) |
| EP (1) | EP2588198A1 (es) |
| JP (1) | JP2013532166A (es) |
| CN (1) | CN103118743A (es) |
| AU (1) | AU2010356582A1 (es) |
| BR (1) | BR112013000027A2 (es) |
| CA (1) | CA2803668A1 (es) |
| EA (1) | EA201370008A1 (es) |
| MX (1) | MX2013000319A (es) |
| WO (1) | WO2012001336A1 (es) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9034318B2 (en) * | 2011-08-30 | 2015-05-19 | The Regents Of The University Of Colorado, A Body Corporate | Chemically modified cystathionine beta-synthase enzyme for treatment of homocystinuria |
| WO2014018873A2 (en) | 2012-07-27 | 2014-01-30 | Chemic Laboratories Inc. | Compositions comprising folic acid derivatives. their preparations and methods of use |
| WO2014089620A1 (en) * | 2012-12-11 | 2014-06-19 | Blackmores Ltd | Compositions and method for maintaining/improving cognitive function |
| US9675678B2 (en) | 2013-01-29 | 2017-06-13 | The Regents Of The University Of Colorado, A Body Corporate | Compositions and methods for treatment of homocystinuria |
| GB201405033D0 (en) | 2014-03-20 | 2014-05-07 | Isis Innovation | Combination therapy |
| CN106535881A (zh) * | 2014-04-14 | 2017-03-22 | N·V·努特里奇亚 | 用于评估和治疗或预防受损的血浆极性脂质水平的方法 |
| NZ741552A (en) | 2015-11-09 | 2022-04-29 | Univ Colorado Regents | Compositions and methods for treatment of homocystinuria |
| JP6256888B2 (ja) * | 2016-02-29 | 2018-01-10 | 高知県公立大学法人 | 健脳食品または健脳飲料およびこれらを投与する方法 |
| CN105748503B (zh) * | 2016-03-14 | 2018-10-23 | 福格森（武汉）生物科技股份有限公司 | 一种含有5-甲基四氢叶酸的复合维生素微丸 |
| US10179144B2 (en) | 2017-02-07 | 2019-01-15 | Roger F. Duronio | Formulations and compositions for rejuvenation of the body |
| US10201577B2 (en) | 2017-02-14 | 2019-02-12 | Keyview Labs, Inc. | Compositions and methods for enhancing working and long-term memory support using new combination of ginkgo biloba and panax ginseng and associated components |
| EP3612214A4 (en) | 2017-04-17 | 2021-01-20 | The Regents of the University of Colorado, A Body Corporate | ENZYME REPLACEMENT THERAPY OPTIMIZATION FOR THE TREATMENT OF HOMOCYSTINURIA |
| JP7312184B2 (ja) | 2017-10-23 | 2023-07-20 | エピトラッカー インコーポレイテッド | 脂肪酸アナログおよび代謝症候群に関連する症状の処置におけるそれらの使用 |
| AU2019274431B2 (en) | 2018-05-23 | 2025-03-13 | Epitracker, Inc. | Compositions and methods for diagnosis and treatment of conditions related to the quality of aging and longevity |
| CN108992458A (zh) * | 2018-06-12 | 2018-12-14 | 中国人民解放军第四军医大学 | 维生素b12用于制备预防和/或治疗术后认知功能障碍药物的应用 |
| CN109498771B (zh) * | 2018-12-06 | 2021-09-28 | 江西恒康药业有限公司 | 一种改善轻度认知功能障碍的靶向组合物及其制备方法 |
| WO2020146263A1 (en) | 2019-01-09 | 2020-07-16 | Epitracker, Inc. | Compositions and methods for diagnosis and treatment of neurodegenerative diseases |
| WO2020180814A1 (en) | 2019-03-04 | 2020-09-10 | Epitracker, Inc. | Fatty acid analogs and their use in the treatment of cognitive impairment, behavioral conditions, and chronic pain |
| PH12021553235A1 (en) | 2019-06-26 | 2022-08-22 | Univ Colorado Regents | Drug product for enzyme therapy for treatment of homocystinuria |
| US11547688B2 (en) | 2019-08-22 | 2023-01-10 | Nodari Rizun | Amino acid compositions and methods of manufacturing the compositions |
| CN115616097B (zh) * | 2021-07-16 | 2024-10-25 | 深圳奥萨制药有限公司 | 叶酸类物质的新用途 |
| CN113712981A (zh) * | 2021-09-06 | 2021-11-30 | 北京斯利安健康科技有限公司 | 甜菜碱组合物及其应用 |
| US12370166B2 (en) | 2021-11-03 | 2025-07-29 | Epitracker, Inc. | Pentadecanoylcarnitine for treatment of conditions related to the quality of aging and longevity |
| CN118453638A (zh) * | 2024-05-22 | 2024-08-09 | 中国人民解放军军事科学院军事医学研究院 | 一种营养组合物及其在线粒体功能损伤修复中的应用 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6008221A (en) | 1996-11-06 | 1999-12-28 | Bristol-Myers Squibb Company | Method for treating Alzheimer's disease with folic acid |
| CA2445512C (en) | 2001-04-25 | 2010-10-12 | Cobalz Limited | A method for treating or preventing a functional vitamin b12 deficiency in an individual and medical compositions for use in said method |
| AU2002345255A1 (en) * | 2001-07-03 | 2003-01-21 | Nutri Pharma Danmark Holding A/S | Composition comprising soy and use thereof in the prevention and/or treatment of various diseases |
| US20090143433A1 (en) | 2004-12-01 | 2009-06-04 | Curt Hendrix | Cocktail for modulation of alzheimer's disease |
| US20070248696A1 (en) * | 2006-04-25 | 2007-10-25 | Mind Sports Nutrition Inc. | Composition and method for enhancing neuromuscular facilitation and cognitive functions |
-
2010
- 2010-09-17 CA CA2803668A patent/CA2803668A1/en not_active Abandoned
- 2010-09-17 EP EP10755230.9A patent/EP2588198A1/en not_active Withdrawn
- 2010-09-17 MX MX2013000319A patent/MX2013000319A/es not_active Application Discontinuation
- 2010-09-17 BR BR112013000027A patent/BR112013000027A2/pt not_active IP Right Cessation
- 2010-09-17 JP JP2013517493A patent/JP2013532166A/ja active Pending
- 2010-09-17 CN CN2010800683893A patent/CN103118743A/zh active Pending
- 2010-09-17 WO PCT/GB2010/051557 patent/WO2012001336A1/en not_active Ceased
- 2010-09-17 EA EA201370008A patent/EA201370008A1/ru unknown
- 2010-09-17 AU AU2010356582A patent/AU2010356582A1/en not_active Abandoned
- 2010-09-17 US US13/807,917 patent/US9364497B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US9364497B2 (en) | 2016-06-14 |
| BR112013000027A2 (pt) | 2017-07-11 |
| EA201370008A1 (ru) | 2013-06-28 |
| WO2012001336A1 (en) | 2012-01-05 |
| EP2588198A1 (en) | 2013-05-08 |
| US20130142769A1 (en) | 2013-06-06 |
| CN103118743A (zh) | 2013-05-22 |
| JP2013532166A (ja) | 2013-08-15 |
| AU2010356582A1 (en) | 2013-02-21 |
| CA2803668A1 (en) | 2012-01-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2013000319A (es) | Tratamiento de transtornos cognitivos. | |
| EA201590870A1 (ru) | АМИНОЗАМЕЩЕННЫЕ ИМИДАЗО[1,2-a]ПИРИДИНКАРБОКСАМИДЫ И ИХ ПРИМЕНЕНИЕ | |
| PH12017502154A1 (en) | Methods for conditioning patients for t cell therapy | |
| EA033374B9 (ru) | Твердые фармацевтические композиции, содержащие энзалутамид, и способ лечения | |
| WO2016025635A3 (en) | Combination therapy for treating cancer | |
| NZ700759A (en) | Combination therapy for treating cancer | |
| WO2013061161A3 (en) | New combination therapies for treating neurological disorders | |
| MX367341B (es) | Tetrahidronaftiridina y compuestos biciclicos relacionados para la inhibicion de la actividad de rorgamma y el tratamiento de enfermedades. | |
| NZ719049A (en) | Cancer treatment with combination of plinabulin and taxane | |
| MY199581A (en) | Plasminogen replacement therapy for plasminogen-deficiency | |
| EA201590654A1 (ru) | Комбинация разагилина и придопидина для лечения нейродегенеративных нарушений, в частности болезни хантингтона | |
| PH12012501740A1 (en) | Treatment of rheumatoid arthritis with a combination of laquinimod and methotrexate | |
| WO2016043874A3 (en) | Combination therapy for treating cancer | |
| MX2015010791A (es) | Metodos para tratar el cancer y prevenir la resistencia a farmacos. | |
| EP4406536A3 (en) | Cystathionine beta-synthase enzyme for treatment of homocystinuria | |
| PH12016500140A1 (en) | Heterobicycloaryl rorc2 inhibitors and methods of use thereof | |
| MX2017017138A (es) | Conjugados homogeneos especificos de sitio con inhibidores de ksp. | |
| HK1218251A1 (zh) | 用拉喹莫德治疗多发性硬化症 | |
| GB201302343D0 (en) | Pharmaceutical compositions comprising 15-OHEPA and methods for using the same | |
| MX2015005733A (es) | Compuestos triciclicos para usarse en el tratamiento y/o control de obesidad. | |
| WO2011106378A3 (en) | Oral b12 therapy | |
| WO2007149816A3 (en) | Strontium compositions and methods of treating osteoporotic conditions | |
| WO2014026013A3 (en) | Methods for maintaining or improving health, well-being and/or a physiological function in a subject | |
| MX350125B (es) | Eprotirom para uso en la prevención y/o tratamiento de trastornos del cabello y composiciones del mismo. | |
| WO2013038200A3 (en) | Neurodevelopmental disorders |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |